Background
==========

Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is an uncommon complication of treatment with the new class of antidepressant agents, the selective serotonin reuptake inhibitors (SSRIs) \[[@B1],[@B2]\]. Estimations of the occurrence of hyponatremia during treatment with SSRIs range between 0.5% and 25%, and the risk of hyponatremia seems to be greatest during the first weeks of treatment with SSRI, in the elderly, in female patients and in patients with lower body weights \[[@B3],[@B4]\]. However, severe consequences of hyponatremia caused SSRIs, such as tonic/clonic seizure, have not been reported. We describe the case of a 61-year-old male with tonic/clonic seizure caused by SSRI-induced hyponatremia

Case Presentation
=================

We recently saw a 61-year-old male referred to us because of a 3-day history of malaise, progressive confusion, and a tonic/clonic seizure. Two weeks before, he had been started on a regimen of citalopram 20 mg at bedtime. The patient and his wife reported that he became progressively confused, lethargic and had difficulty performing simple tasks. He is a type 2 diabetic treated with metformin 500 mg twice daily and glyburide 2.5 mg once daily. Upon admission, the patient was afebrile with normal vital signs. He appeared euvolemic without evidence of congestion or dehydration. Neurologic examination was normal except for decreased strength on lower extremities. Significant laboratory findings included sodium of 124 mmol/L (136--145 mmol/L), potassium of 4.3 mmol/L (3.5--4.5 mmol/L), chloride 86 mg/dL (98--106 mmol/L), blood urea nitrogen of 3.2 mmol/L (3.6--7.1 mmol/L), creatinine 79.56 μmol/L (\< 133 μmol/L), glucose of 10.49 mmol/L (4.2--6.4 mmol/L), a uric acid of 150 μmol/L (150--480 μmol/L) and a serum osmolarity of 263 mosm/L (285--295 mOsm/L). Urine sodium and urine osmolarity were elevated, 141 mEq/L, and 400 mosm/L, respectively. A CT of the head and an EEG were both normal. An AM cortisol level, thyroid-stimulating hormone (TSH) and free thyroxine levels were within normal limits. Results of a urine toxicology screen revealed no presence of ethanol or recreational drugs. A citalopram pill count confirmed compliance with the drug regimen without evidence of overdose.

A diagnosis of SIADH was made based on clinical euvolemia in the presence of hyponatremia with a urine osmolarity and sodium that were inappropriately high. Normal renal, thyroid and adrenal function with relative hipouricemia, all supported SIADH. Extensive investigations ruled out malignancy, pulmonary, hepatic cardiac or renal disease or any other known causes of SIADH.

On the day of admission, citalopram was discontinued and the patient was treated with 2 liters of intravenous 0.9% sodium chloride, phenytoin (5 mg/kg), and subcutaneous insulin. Approximately 24 hours after admission the patient\'s serum sodium increased to 129 mmol/L (136--145 mmol/L) and the chloride increased to 89 mmol/L (98--106 mmol/L), thereafter, fluids were restricted to 1200 ml/day. His mental status improved over the next 48 hours. Five days after admission serum sodium was 134 mEq/L (136--145 mmol/L) and serum chloride was 99 mmmol/L (98--106 mmol/L). Patient was fully alert, had no more seizures and was subsequently discharged. At this time phenytoin treatment was stopped. A follow up serum sodium three weeks after discharge was 135 mmol/L (136--146 mmol/L).

This patient\'s seizures appear to have been induced by hyponatremia that was secondary to SIADH, a diagnosis that is supported by the low serum sodium concentration, concentrated urine, and clinical evidence of euvolemia. The laboratory values and history were inconsistent with a diagnosis of psychogenic polydipsia. The finding of SIADH secondary to citalopram use may reflect dysregulation of serotonergic control of ADH release or metabolism. Experimental evidence in rodents has demonstrated the presence of serotonin\'s neurons in the hypothalamic supraoptic nucleus, which is where the ADH prohormone is synthesized\[[@B5]\]. Other studies suggest that serotonin may be involved in the regulation of ADH release\[[@B6]\]. The occurrence in this case of a seizure secondary to SIADH-associated hyponatremia suggests a possible mechanism for citalopram-induced convulsions and corroborates previous reports of citalopram-induced SIADH.

Conclusions
===========

The present case and others previously reported, emphasize the need for greater awareness of the development of this serious and potentially fatal complication in association with citalopram therapy. Review of the present and previous cases has shown that the onset of citalopram-induced hyponatremia or SIADH ranges from 6 to 20 days after the therapy has been started \[[@B7]-[@B16]\]. Potential risk factors for SIADH due to citalopram included advanced age, female gender, concomitant use of medications known to cause SIADH or hyponatremia, and possibly, higher citalopram doses \[[@B7],[@B8],[@B17]\]. Therefore, a high level of suspicion, close and careful monitoring of serum sodium concentration particularly in elderly patients during the first month of therapy with citalopram may reduce the incidence of this serious and likely, not rare, adverse effect.

Although information is not conclusive, other SSRI\'s should also be avoided if treatment with an antidepressant had to be restarted in patients with past medical history of hyponatremia or SIADH induced by citalopram \[[@B17],[@B18]\].
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